Search for a trial

Short- and long-term effects of oxytocin on empathy in autistic male adults.

Our study aims at investigating whether male adults with ASD differ from healthy male adults in their neurophysiological responses to positive and negative empathy-evoking pictures when taking oxytocin intranasally once. To this end we will compare…

Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and
Autism Spectrum Disorder (ASD)

The Primary objective is: 1) To investigate clinical effectiveness of the glutamatergic compound memantine in paediatric patients with: - Obessive-Compulsive Disorder (OCD) GOAT-1 - Autism Spectrum Disorder (ASD) GOAT-2 with respect to symptoms of…

Genetic causes of 'TOS' (developmental language disorder)

With this study, we aim to shed light on the possible use of diagnostic next generation sequencing in DLD, by determining the diagnostic yield of WGS in this important class of neurodevelopmental disorder. In addition to determining this diagnostic…

The impact of communication possibilities on psychosocial difficulties in children with hearing loss

The primary objective of this study is to determine the effect of specific communicative abilities (speech recognition in noise; vocal emotion recognition and emotion expression) in children with hearing loss on their psychological (emotional and…

Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.

The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children and adolescents aged from 7 to less…

CompAS
The effect of a high intensive training in augmentative and alternative communication on communicative possibilities in patients with Angelman Syndrome

The aim of the study is to investigate the effect of an intensive high frequent parental coaching intervention on communicative abilities in patients with AS. Patients with AS who receive standard care, will serve as controls. Parents/caretakers in…

A Randomized, investigator/subject blind, adaptive, single and multiple ascending dose, placebo-controlled study to investigate safety, tolerability , pharmacokinetics, pharmacodynamics, food effect and taste of RO7017773 following oral administration in healthy participants.

Part 1, 2 and 3;To assess the safety and tolerability of single and multiple ascending doses of RO7017773 in healthy participants.To investigate the PK of RO7017773 in plasma and urine.To investigate the PD effects of RO7017773 treatment on specific…

Autism spectrum disorder: developmental course from childhood to adulthood and predictors for societal participation

The objective of this study is to determine the changes over time of ASD symptoms and co-occurring psychiatric symptoms from childhood to adulthood and to investigate societal participation in adulthood, with an emphasis on education and employment.

SCOPE for improvement of direct care in early childhood: A Social COmmunication Programme supported by E-health for early identification and intervention of social communication problems possibly associated with autism in primary care

Primary Objective:The main objective of this study is to investigate the effectiveness of BEAR (a parent training combining e-learning and home visits) compared to care-as-usual (CAU) in young children (12-30 months) who are at risk of developing…

The efficacy of EMDR in youngsters with autism

The primary objective of the study is to determine if EMDR reduces the core symptoms of ASD and daily experienced stress in youngsters diagnosed with ASD.

Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.

The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.